Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
July 31, 2023 6:59 AM EDTCash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disordersBrain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to dateBiohaven anticipates initiating a Phase 2 clinical trial in Parkinson's disease and... More
